News

Medigene Granted Additional Patent for RhuDex® for the Treatment of Autoimmune Diseases

Martinsried/Munich, 13 December 2013. The biotech company Medigene AG (Frankfurt: MDG1, Prime Standard) announces that the European Patent Office has granted an additional  patent protecting the drug candidate RhuDex®, which is currently being developed by Medigene for the treatment of autoimmune diseases. The term of the patent EP 1991548 granted for the choline salt in RhuDex® ends in 2027, with a potential extension of up to five years.

Dr. Frank Mathias, Chief Executive Officer of Medigene AG, comments: "This RhuDex® patent further expands the protection of our phase II drug candidate and acknowledges Medigene's continuous work on its development projects."

RhuDex®: Medigene is developing RhuDex® as an oral, disease-modifying drug for the treatment of autoimmune diseases. RhuDex® is a CD80 antagonist that blocks undesired T-cell activation, and thus has an immunomodulating and anti-inflammatory effect. Safety and tolerability of RhuDex® has already been demonstrated in several phase I clinical trials. Medigene has successfully completed a phase IIa pilot study with RhuDex® in the indication rheumatoid arthritis. Currently Medigene is planning to conduct a phase II trial in primary biliary cirrhosis (PBC), in order to confirm the mode of action of RhuDex® in autoimmune diseases.

Primary biliary cirrhosis (PBC): The autoimmune disease PBC is a chronic liver disease that initially affects the bile ducts. The bile ducts are progressively destroyed by inflammatory processes, causing biliary stasis and build-up of bile in the liver. Liver tissue is destroyed and replaced by connective tissue, and liver cirrhosis develops.

Medigene AG (Frankfurt: MDG, prime standard) is a publicly listed biotechnology company headquartered in Martinsried/Munich, Germany. Medigene focuses on clinical research and development of novel drugs against cancer and autoimmune diseases. Medigene was the first German biotech company to have revenues from marketed products, which are distributed by partner companies. It has two drug candidates in clinical trials, EndoTAG®-1 and RhuDex®, and is developing an innovative vaccine technology. For more information, please visit www.medigene.com.

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® and RhuDex® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.


Contact
Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor@medigene.com

To unsubscribe from the press release distribution list, please go to www.medigene.com/unsubscribe.